

CTEP Clinical Oncology Research Enterprise (CORE)

7/12/17 Michael Montello, PharmD, MBA montellom@mail.nih.gov 1



Agenda

- Overview of CORE
- Enhancing safety reporting
- Improving data quality; auditing; and monitoring processes
- Streamlining regulatory compliance
 - Registration and Credentialing repository (RCR): Electronic investigator registration (1572)
 - Delegation of Tasks Log (DTL)

Why CORE?

Clinical Oncology Research Enterprise (CORE) represents the development of an integrated IT solution that:

- Addresses evolving and more complex science (ex. Biomarkers, imaging, precision medicine trials, genomics and correlative studies)
- Modernizes underlying architecture and technology
- Implements scalable and configurable technology to meet new/future requirements
- Emphasis on improving data quality and control
- Enhanced regulatory compliance (CFR-11; GCP; NIST; FISMA)


CORE & Clinical Trials


CTEP CORE supports CTEP, other NCI staff, and the extramural community in the following clinical trial domains:


- Information Security
- Study Administration and Logistics
- Clinical Data Capture and Reporting
- Correlative Study Data
- Regulatory Monitoring and Reporting
- Data Quality and Control



CTEP CORE – End to End Clinical Trial Process Support








CTEP-Adverse Event Reporting System (CTEP-AERS) /Rave Integration

Goal: Promote serious and routine safety reporting into a single harmonized process by integrating CTEP-AERS and Rave

- Reduce <u>under</u>-reporting of Serious Adverse Events (SAEs)
- Reduce <u>over</u>-reporting of SAEs
- Improve timeliness of AE reporting
- Create a single source of AE data
- Eliminate need for reconciliation
- Reduce administrative burden on the entire oncology community (treating site; lead protocol organization stat & ops offices; NCI; FDA)

Improve efficiency while promoting patient safety



Rave/CTEP-AERS Status

- Pilot 2016 (limited functionality):
 - 5 pilot studies
 - ~1,000 SAEs reported
- Full functionality available for new <u>NCI-held IND</u> studies as of Mid-March
- NCI requires use for new NCI IND studies activated after July 1, 2017
 - Several organizations have self-elected to launch for studies prior to 7/1/17
- Expanded functionality to support Network Group held IND or commercial agent studies to be available 1st quarter of 2018

Question for CTAC: How can CTEP CORE better serve the oncology community?

Other questions?



Auditing & Monitoring


Rocio J. Paul, MSHS, CCRP rocio.paul@nih.gov July 12, 2017

Auditing vs. Central Monitoring

Parameter	Auditing	Central Monitoring			
Frequency	Typically a retrospective review; audit scheduled every 1 to 3 years*	Continuous monitoring (intervals) of data during the conduct of the study			
Patient Coverage	10 – 20 % of the total patients enrolled onto a clinical trial are reviewed	All patients or subset of patient data are reviewed			
Data points reviewed	A comprehensive list of data points.* Also may review data points on-site that have been monitored remotely	Selected critical data points prospective defined in the protocol's monitoring pla			
Conducted by & location	Audit conducted by Lead Organization (LO); data reviewed on-site*	Monitoring conducted by Lead Organization (LO); data reviewed off-site			
Tool used [New]	Targeted Source Data Verification (TSDV)	Source documents uploaded by sites into portal for verification against eCRF data			
Verification of Source Data [New]	Actual source document verified at the site	The uploaded copy of source document is reviewed remotely in Rave			

* Based on NCI/CTEP CTMB Audit Guidelines.


Enhancing the QA Program



- Database used for auditing functions (scheduling audits; site, protocol and patient selection; generating audit reports; etc.)
- Repository for all audit information (including audit findings & reports, correspondence; CAPA plans, etc) for across multiple organizations
- Tool used within RAVE [Clinical Data Management System]
- Enables source data verification to be recorded
- Centralized monitoring
 approach to be implemented
- Mechanism allowing sites to upload source documents selected for review to a CM Portal
- Collects information from the AIS, RAVE, TSDV, CMP, others
- Generates reports of queries that are pending or delinquent; and eventually other types of reports

Auditing Utilizing TSDV Tool

The use of the Targeted Source Data Verification (TSDV) tool enables the ability to 'record' Source Data Verification activity in Rave




Central Monitoring (CM) Augmenting the TSDV Process

ICH E6 (R2) - ADDENDUM of 5.18.3 Extent and Nature of Monitoring (Nov 2016)

- <u>The sponsor should develop</u> a systematic, prioritized, <u>risk-based approach</u> to monitoring clinical trials. ... <u>The sponsor may choose ...combination of</u> <u>on-site and centralized monitoring, or ...centralized monitoring</u>. The sponsor should document the rationale for the chosen monitoring strategy (e.g., in the monitoring plan).
- Centralized monitoring is a remote evaluation of accumulating data, performed in a timely manner...

Central Monitoring (CM)




Central Monitoring (CM) View by Protocol & by Site

Protocols Dashboard	and the second se	SWOG User. Visit par GTEX Rave/DQP	inical Data		boration Delegation	and the second	ch for
ueries DQP DTI		Portal Central Monit					
al Monitoring > 1	MN001 Sour	ce Document Repos	sitory		Upload New I	Document 4 doc	uments are missing
ocol: ALL		Site:	ALL	T	Patient:	ALL	V
6° 🖉 🕚	/N001 Source	e Documents					
Protocol	Site	Patient	# Documents Expected	Documents Uploaded	# Missing Documents	# Days Document has been Missing	
A081105	MN001	14602 M	4 essage	4	0	0	Click to see
EAY131	MN001	1460 reg	garding	2	0	0	missing documents
NRG-GU002	MN001	B 1460		3 🕐	2	4	<u> </u>
S1400	MN001	14605	6	4	2	10	6
A151216	MN001	14606	7	7	0	0	6
E1A11	MN001	14607	8	8	0	0	6


Central Monitoring (CM)

View by Protocol Data Points View Status								
Data Point	Need Review?	DOC Needed for Review	Entered?	Expected Date for SD Upload	Missing DOCs?	Uploaded DOCs?	Triage?	Data Points Reviewed?
DP1	\square	Informed Consent	\square	Data Entry+7	Yes	Yes	Yes	Yes
DP2	\checkmark	Radiology Report	\square	Data Entry+7	Yes	No	N/A	No
DP3	\checkmark	Informed Consent	\checkmark	Data Entry+7	Yes	Yes	Yes	Yes
	Lead Org Monitor Reviews; Compares SD to Data on eCRF							

Data Quality Portal (DQP)



In the Future...



Questions?



Registration and Credential Repository (RCR) and Delegation of Tasks Log (DTL)

Matt Boron RPh boronm@mail.nih.gov

Registration and Credential Repository (RCR)

- Provides an online registration application with electronic signature
- Define specific Registration Types

• Registration Type will dictate documentation requirements

Registration and Credential Repository (RCR)

- Electronic FDA Form 1572
- NCI Biosketch
- Financial Disclosure Form
- Designee Form

Registration and Credential Repository (RCR)

- Requires registration in NCI IAM (Identity and Access Management) application
 - Unique profile for each individual
 - Access credentials
 - Provide access to CORE applications
 - Allows for RCR profile owners to electronically sign their registration documents
- Electronic collection of data and certificates allows for
 - sharing across NCI network
 - Control of downstream processes

Registration and Credential Repository – Summary screen

SUMMARY PRIMARY CONTACT INFO FORM FDA 1572 NCI BIOSKET	CH FDF AGENT SHIPMENT FORM PRACTICE PREFERENCES SUBMITTED DOCUMENT	S REVIEV	W AND APPROVE		
Personal Info			Registration Info		
CTEP Person ID	Name		Status	Expiration Date	
IVR -	Dr.		Active	19-NOV-2017	
Comments			Registration Coordinator		
Comments			CTEP ID-Name		
			Comments		
	10		Comments		
	✔ Edit Comments				10
	P cut comments				
Deleter the Constant Information			6		
 Primary Contact Information 			Group Affiliations		
Name	Address			Group Name	
KY049-Norton Hospital Pavilion and Medical Campus	231 East Chestnut Street, Louisville, KY-40202 USA		Children's Oncology Group		\$
			L		
Phone	Email				
(502)	Email				
Practice Sites			┌─ IRBs ────		
Practice sites			IRDS		
CTEP ID	Site Name		IRB Number	IRB Name	
KY027 Norton Children's Hospital KY049 Norton Hospital Pavilion and Medical Campus				No Records to Display	\$
- Shipping Info			Task Access		
Shipping Type	Shipping Designee		Ta: Drug Shipment Investigator	sk	Allowed
PSD	A -		Consenting Person		Yes
Practice Site	Address		Enrolling Person		Yes
KY027-Norton Children's Hospital			Site Protocol PI		Yes 🔻
Krozz-Norton Children's Hospital	Pharmacy, 231 East Chestnut Street, Sixth Floor, Louisville, KY-40202 USA				

Delegation of Tasks Log (DTL) - Development

- CTEP and Lead Protocol Organizations (LPOs) collaborate during LOI / Concept / Protocol development to determine if DTL is needed
- Clinical Investigator reviews and signs the protocol and site– specific DTL
- Site/protocol activation based on completed DTL and other protocol-specific requirements (PSRs)
- DTL controls downstream system access and protocol conduct

Delegation of Tasks Log (DTL) - Purpose

- Identify the Clinical Investigator (CI) and Delegation of Tasks Log Administrator (DTLA)
- Provides a complete list of investigators and sub-investigators
- Identifies individuals that can perform designated tasks on the protocol
- Track changes in task assignment over study lifecycle

Delegation of Tasks Log (DTL) – Protocol Template

Site DTL Browser

Delegation Log > Site DTL Browser > Initiate Site Delegation Log

Template Information 🛛 🛸	Site:	Mercy Hospital(MN019) *	Protocol: A0	51301	•			
Document Number: A051301	2	🚪 Task List						
Document Type: Protocol	#	Task	Primary?	Primary? Required? -		Registration	Rostered?	Training Requirements
Document Title: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following	1	DTL Administrator	Yes	Yes	Required? Yes	Type IVR NPIVR AP	Yes	Requirements
Autologous Stem Cell Transplantation Versus Placebo in Patients with	2	Clinical Investigator	Yes	Yes	Yes	IVR NPIVR	Yes	
Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated	3	Enrolling Person/Treating Investigator	No	Yes	Yes	IVR NPIVR	Yes	
B-cell Subtype Lead Group: ALLIANCE	4	Consenting Person	No	Yes	Yes	IVR NPIVR AP	Yes	
Template Status: Activated Template Revision: 12-JUN-2017	5	HP Assessments	No	Yes	No	IVR NPIVR	Yes	
11:02 AM	6	Tox Assessment	No	Yes	Yes	IVR NPIVR	Yes	
	7	Eligibility Assessment	No	Yes	No	IVR NPIVR	Yes	
Displays DTL	8	Rave CRA	No	Yes	No	IVR NPIVR AP	Yes	
template information and required tasks	9	OPEN Registrar	No	Yes	No	IVR NPIVR AP	Yes	
	10	Study-Related Interventions	No	Yes	No	IVR NPIVR	No	

Initiate DTL

Delegation of Tasks Log (DTL) – site log

Site DTL Browser

Delegation Log > Site DTL Browser > Manage Site Delegation Log DTL Summary Assignee Task Status All Show changes after last Active, Awaiting_CI_Appr V Site DTL Status: Initiated Ait + approval View by Assignee Site DTL Status Reason: N/A Template Revision: 12JUN2017 Task Assignments List for MN019, Protocol A051301 24 11:02:10 AM Start End Assignee . Task Name Status Status Reason Action Template Status: Activated Date Date Name Clinical Protocol Number: A051301 Tan, =0 1 Awaiting_CI_Approval Annie Investigator Protocol Status: Active Horn, DTL =0 2 Awaiting CI Approval Administrator Amanda Protocol Title: A Randomized Double-Blind Phase III Study of Tan. Consenting 3 =0 Awaiting CI Approval Annie Person Ibrutinib During and Following Autologous Stem Cell Transplantation Horn, Consenting 4 Awaiting CI Approval =0 Versus Placebo in Patients with Amanda Person Relapsed or Refractory Diffuse Large Tan, Eligibility 5 Awaiting_CI_Approval B-cell Lymphoma of the Activated Assessment Annie Show Inactive Task Assignments Assignee All Task All B-cell Subtype Eligibility Horn, 6 Awaiting CI Approval Amanda Assessment Site: MN019 Task Assignment List Enrolling Tan, Site Name: Mercy Hospital 7 Person/Treating Awaiting CI Approval Annie Investigator Assignee Tasks Site Registration Status: HP Tan, 8 Awaiting CI Approval Last Updated By: HAASA Annie Assessments Awaiting_CI_Approval Task Assignments HP Horn, Last Updated Date: 19-JUN-2017 9 Awaiting_CI_Approval Assessments Tan, Annie Clinical Investigator Consenting Person Eligibility Assessment Enrolling Person/Treating Investigator HP Assessments Amanda Last Approved By: Horn. Study-Related Interventions Tox Assessment 10 **OPEN Registrar** Awaiting CI Approval Amanda Last Approved Date: N/A Haas, 11 Rave CRA Awaiting_CI_Approval Awaiting CI Approval Task Assignments Audrey Tasks Assigned Horn, Horn, DTL Administrator Consenting Person Eligibility Assessment HP Assessments OPEN Registrar Rave CRA 12 Rave CRA Awaiting_CI_Approval Amanda Amanda Clinical Investigator Study-Related Interventions Study-Related Tan, 13 Awaiting_CI_Approval DTL Administrator Annie Interventions Awaiting CI_Approval Task Assignments ✓ Consenting Person Horn. Study-Related 14 Awaiting_CI_Approval Haas, Audrey Amanda Interventions Rave CRA Eligibility Assessment Tan. Tox 15 Awaiting_CI_Approval Annie Assessment Enrolling Person/Treating Investigator Assign Tasks Submit DTL

Benefits of NCI Proposed Process

- Complies with FDA investigator and sub-investigator data collection requirements
- Leverages data capture across multiple NCI integrated applications to ensure only qualified investigators are participating
- Controls protocol-specific research tasks based on the DTL
- Decreases burden on investigators through use of a single NCI-specific registration packet
- Increases accuracy, efficiency, and coordination between NCI and sites

Benefits to NCI Proposed Process Leveraging RCR and DTL to ensure regulatory compliance

- Active 1572 + Active DTL role

Study participation (ex. pt. registration)

- Inactive 1572 + Active DTL role _____ Study participation

- Active 1572 + Inactive DTL role - Study participation

QUESTIONS?

Reserve slides



RCR/DTL Process Workflow

